CA2084290A1 - Inhibition des maladies liees aux voies de la 5-lipoxygenase et de la cyclooxygenase - Google Patents

Inhibition des maladies liees aux voies de la 5-lipoxygenase et de la cyclooxygenase

Info

Publication number
CA2084290A1
CA2084290A1 CA002084290A CA2084290A CA2084290A1 CA 2084290 A1 CA2084290 A1 CA 2084290A1 CA 002084290 A CA002084290 A CA 002084290A CA 2084290 A CA2084290 A CA 2084290A CA 2084290 A1 CA2084290 A1 CA 2084290A1
Authority
CA
Canada
Prior art keywords
alkyl
alkenyl
pyridyl
formula
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002084290A
Other languages
English (en)
Inventor
Jerry L. Adams
Paul E. Bender
Timothy F. Gallagher
John R. Heys
Carl Perchonock
Anthony J. Villani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2084290A1 publication Critical patent/CA2084290A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002084290A 1990-06-12 1991-06-07 Inhibition des maladies liees aux voies de la 5-lipoxygenase et de la cyclooxygenase Abandoned CA2084290A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53719590A 1990-06-12 1990-06-12
US537,195 1990-06-12

Publications (1)

Publication Number Publication Date
CA2084290A1 true CA2084290A1 (fr) 1991-12-13

Family

ID=24141624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002084290A Abandoned CA2084290A1 (fr) 1990-06-12 1991-06-07 Inhibition des maladies liees aux voies de la 5-lipoxygenase et de la cyclooxygenase

Country Status (10)

Country Link
EP (1) EP0533837A4 (fr)
JP (1) JPH05508153A (fr)
KR (1) KR930700104A (fr)
AU (1) AU8205991A (fr)
CA (1) CA2084290A1 (fr)
IE (1) IE911977A1 (fr)
NZ (1) NZ238485A (fr)
PT (1) PT97960A (fr)
WO (1) WO1991019497A1 (fr)
ZA (1) ZA914491B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679396A1 (fr) * 1994-03-02 1995-11-02 Pfizer Inc. Utilisation de dérivés oxindol-2-carboxamides-1,3-substitués pour la fabrication d'un médicament destiné au traiter des dommages du myocardes causés par une ischémie et les dommages du myocardes induits par les cytokines
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
EP0833622B8 (fr) * 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprenant un inhibiteur de cyclooxygenase-2 et un inhibiteur de 5-lipoxygenase
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
YU11900A (sh) 1997-09-05 2002-11-15 Glaxo Group Limited Derivati 2,3-diaril-pirazolo (1,5-b) piridazina, njihovo dobijanje i njihova upotreba kao inhibitora ciklooksigenaze 2(cox-2)
EP1037639A4 (fr) 1997-12-19 2002-04-17 Smithkline Beecham Corp .0mposes d'imidazole heteroaryle substitues, leurs compositions et usages pharmaceutiques
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
JP2003525201A (ja) 1998-08-20 2003-08-26 スミスクライン・ビーチャム・コーポレイション 新規な置換トリアゾール化合物
ES2228127T3 (es) 1998-11-03 2005-04-01 Glaxo Group Limited Derivados de pirazolopiridina como inhibidores selectivos de cox-2.
EP1126852B1 (fr) 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyrazines substitues pyridin-4-yle ou pyrimidin-4-yle
US6498166B1 (en) 1999-02-27 2002-12-24 Smithkline Beecham Corporation Pyrazolopyridines
CN1255406C (zh) * 1999-11-10 2006-05-10 奥索-麦克尼尔药品公司 取代的2－芳基－3－(杂芳基)－咪唑并[1，2－a]嘧啶类化合物以及相关的药物组合物和方法
US7053099B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
EP1233950B1 (fr) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-ones comme inhibiteurs de csbp/p38 kinase
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
ATE300541T1 (de) 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridinderivate
WO2002048147A2 (fr) 2000-12-15 2002-06-20 Glaxo Group Limited Composes therapeutiques
DE60201074T2 (de) 2001-03-08 2005-09-15 Smithkline Beecham Corp. Pyrazolopyridinderivate
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
WO2002078700A1 (fr) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, leur procede de preparation et leur utilisation en tant que composes therapeutiques
DE60212949T2 (de) 2001-04-10 2007-01-04 Smithkline Beecham Corp. Antivirale pyrazolopyridin verbindungen
US6962914B2 (en) 2001-04-27 2005-11-08 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
ATE337316T1 (de) * 2001-06-21 2006-09-15 Smithkline Beecham Corp Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
DE60211539T2 (de) 2001-10-05 2006-09-21 Smithkline Beecham Corp. Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
US7199120B2 (en) 2001-12-11 2007-04-03 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
US7153863B2 (en) 2002-10-03 2006-12-26 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridline derivatives
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
WO2009005675A1 (fr) 2007-06-28 2009-01-08 Abbott Laboratories Nouvelles triazolopyridazines
US20120220581A1 (en) 2009-10-30 2012-08-30 Janssen-Cilag, S.A. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
US8703760B2 (en) 2009-12-18 2014-04-22 Mitsubishi Tanabe Pharma Corporation Antiplatelet agent
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
WO2013000924A1 (fr) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv Dérivés de 1-aryl-4-méthyl-[1,2,4]triazolo[4,3-a]quinoxaline
CA2872216C (fr) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinaisons comprenant des inhibiteurs de la pde 2 tels que des composes 1-aryl-4-methyl-[1,2,4]triazolo [4,3-a]-quinoxaline et des inhibiteurs de la pde 10 pour utilisation dans le traitement de troublesneurologiques ou metaboliques
JP6174695B2 (ja) 2012-07-09 2017-08-02 ヤンセン ファーマシューティカ エヌ．ベー． ホスホジエステラーゼ１０酵素の阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW24186A1 (en) * 1985-12-12 1987-07-08 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US5002941A (en) * 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
AU6355190A (en) * 1989-06-13 1991-01-17 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages

Also Published As

Publication number Publication date
EP0533837A4 (en) 1994-11-17
EP0533837A1 (fr) 1993-03-31
WO1991019497A1 (fr) 1991-12-26
AU8205991A (en) 1992-01-07
PT97960A (pt) 1992-03-31
ZA914491B (en) 1992-12-30
NZ238485A (en) 1994-03-25
IE911977A1 (en) 1991-12-18
JPH05508153A (ja) 1993-11-18
KR930700104A (ko) 1993-03-13

Similar Documents

Publication Publication Date Title
CA2084290A1 (fr) Inhibition des maladies liees aux voies de la 5-lipoxygenase et de la cyclooxygenase
JP6132410B2 (ja) ホスファチジルイノシトール３−キナーゼのイソインドリノンインヒビター
JPH06503349A (ja) 新規ｃｓａｉｄｓ
WO1990003789A1 (fr) DERIVES DE PYRROLO[1,2-a]IMIDAZOLE ET D'IMIDAZO[1,2-a]PYRIDINE ET LEUR EMPLOI COMME INHIBITEURS DE LA VOIE DE LA LIPOXYGENASE 5
US9029392B2 (en) Quinoline derivatives as kinase inhibitors
US5508300A (en) Dihydro pyrazolopyrroles, compositions and use
US20240043440A1 (en) Compositions and methods of modulating short-chain dehydrogenase activity
AU9137591A (en) Novel csaids
JPH05503919A (ja) 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
US8536339B2 (en) AZA-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
KR20020082858A (ko) 1,5-이치환된-3,4-디히드로-1ｈ-피리미도[4,5-ｄ]피리미딘-2-온 화합물 및 ｃｓｂｐ/ｐ38 키나제 매개된 질환의치료시 이들의 용도
JPS62153286A (ja) ５−リポキシゲナ−ゼ経路の抑制
WO1996012703A1 (fr) Composes heteroalkyle et heteroarylthioalkyle thiophenoliques inhibiteurs de la 5-lipoxygenase
WO2023215803A2 (fr) Inhibiteurs de cytochrome bd oxydase et leurs utilisations
AU2008350293A1 (en) Antibiotic tetrahydro-beta-carboline derivatives
FR2911605A1 (fr) Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
EP0306300B1 (fr) Dérivés de pyrrolo[1,2-a]imidazole et imidazo[1,2-a]pyridine et leur utilisation comme inhibiteurs de la 5-lipoxygénase
US8853248B2 (en) (1,2,3-triazolyl)sulfonyl derivatives
US4542140A (en) Pyridinyl substituted ketenemercaptal derivatives
JPS61233675A (ja) ピペラジン化合物
CA2000258A1 (fr) Pyrrolo[1,2-a]-imidazole et derives imidazo[1,2-a]-pyridine et usages comme inhibiteurs de la voie de la 5-lipoxygenase
JPS62153274A (ja) ５−リポキシゲナ−ゼ経路の抑制
JPS61205276A (ja) 複素環式化合物
MXPA00000223A (en) Fused 1,2,4-thiadiazine derivatives, their preparation and use
KR20070032264A (ko) 헬퍼티세포-2에서 발현되는 유사수용체 유도성 물질에길항성을 갖는 화합물

Legal Events

Date Code Title Description
FZDE Dead